

Cell Type
CAR+CD3+
CD19+
Cells / µL
100
1
0.01
Day
1
4
8
11
15
22
30
CAR+ CD3+
CD19+

FIG. 1



Median Cells/µL Over Time by Dose Level
CAR+ CD3+: DL1
CAR+ CD3+: DL2
CD19+: DL1
CD19+: DL2
CAR+CD3+:DL2
CAR+CD3+:DL1
CD19+:DL2
CD19+:DL1
Cells/uL, Median
10000
1000
100
10
1
0.1
0.01
Study Day
1 4 8 11 15 22 30 60 90
Patients, N = 16
Samples, n
CAR+ CD3+: DL1 6 5 6 6 6 6 6 6 5
CAR+ CD3+: DL2 9 10 10 10 10 10 10 6 4
CD19+: DL1 6 5 6 6 6 6 6 6 5
CD19+: DL2 9 10 10 10 10 10 10 6 4

FIG. 2

FIG. 3A



IL-16
Solid line: time to first onset of NE
Max G0
*Max G1
Max G2~3
Picograms/mL
(log value)
3.5
3.0
2.5
2.0
Pretreatment
1
5
10
15
20
25
30
Day(s) From Dose

FIG. 3B



TNF
Solid line: time to first onset of NE
Max G0
*Max G1
Max G2~3
Picograms/mL
(log value)
1.5
1.0
0.5
Pretreatment
1
5
10
15
20
25
30
Day(s) From Dose

FIG. 4A



PD
SD
PR/nPR
CR/CRi
Best Overall Response (%)
100
90
80
70
60
50
40
30
20
10
0
Total
DL1
DL2
45.5% (n=10)
36.4% (n=8)
13.6% (n=3)
4.5% (n=1)
66.7% (n=6)
11.1% (n=1)
22.2% (n=2)
30.8% (n=4)
53.8% (n=7)
7.7% (n=1)
7.7% (n=1)
CR/CRi
PR/nPR
SD
PD

FIG. 4B



uMRD (10-4) at Any Time Point (%)
100
90
80
70
60
50
40
30
20
10
0
Blood, flow
Bone marrow, NGS
Blood, flow
Blood, Bone marrow, NGS
Blood, flow
Blood,marrow, NGS
Blood, flow
Bone marrow, NGS
75% (n=15)
65% (n=13)
75% (n=6)
75% (n=6)
75% (n=3)
Total
DL1
DL2

FIG. 5



DL1
Patients
DL2
1
30
60
90
120
150
180
210
240
270
300
330
360
390
Progression
Progression
Progression
Progression
Progression
CR/CRi
PR
SD
PD
ND
Death
Undetectable MRD, Blood[b]
Undetectable MRD, Bone Marrow[b]
Detectable MRD, Blood
Detectable MRD, Bone Marrow

FIG. 6



CAR+ CD3+: DL1
CAR+ CD3+: DL2
CD19+: DL1
CD19+: DL2
CAR+CD3+:DL2
CAR+CD3+:DL1
CD19+:DL2
CD19+:DL1
Cells/uL, Median[a]
1000
100
10
1
0.1
0.01
1 4 8 11 15 22 30 60 90
Study Day
Number of Samples
CAR+ CD3+: DL1 8 8 9 9 9 9 9 8 8
CAR+ CD3+: DL2 14 13 14 14 14 14 14 13 12
CD19+: DL1 8 8 9 9 9 9 9 8 8
CD19+: DL2 14 13 14 14 14 14 14 13 12

FIG. 7A



PD
SD
PR/nPR
CR/CRi
81.5%
(95% CI, 59.7–94.8)
n=18/22
89%
(95% CI, 51.8–99.7)
n=8/9
45.5%
(n=10)
33%
(n=6)
14%
(n=3)
4.5% (n=1)
67%
(n=6)
22%
(n=2)
11%
(n=1)
CR/CRi
PR/nPR
SD
PD
Best Overall Response (%)
100
90
80
70
60
50
40
30
20
10
0
Total[a]
(N=22)
Failed BTKi and
Venetoclax[b] (n=9)

FIG. 7B



uMRD[a] (10–4) was achieved in 75% (blood)
and
65% (marrow) of patients
Blood, flow
Bone marrow, NGS
Blood, flow
Bone marrow, NGS
75%
(n=15)
65%
(n=13)
37.5%
(n=7)
75%
(n=6)
uMRD (10–4) at Any Time Point (%)
100
90
80
70
60
50
40
30
20
10
0
Total[c]
(N=20)
Failed BTKi and
Venetoclax[b,d] (n=8)

FIG. 8




Failed BTKi and Venetoclax
Other Patients
1 30 60 90 120 150 180 210 240 270 300 330 360 390 420 450 480 510 540 570 600
Progression-Free Time (Days)
CR/CRi PR SD PD ND Death ★MRD, Blood○MRD, Bone Marrow
RT
PD

FIG. 9


CAR+ CD3+ All Failed BTKi and Venetoclax
CD19+ All Failed BTKi and Venetoclax
Median Cells/µL Over Time
CAR+ CD3+ Failed BTKi and Venetoclax
CAR+ CD3+
CD19+
CD19+ Failed BTKi and Venetoclax
Cells/µL, Median
1000
100
10
1
0.1
0.01
1 4 8 11 15 22 30 60 90 180 270 360 450
Visit/Study Day (Log Scale)
CAR+CD3+ Number of Samples
All 22 21 23 23 23 23 21 20 15 13 9 4
Failed BTKi and Venetoclax 8 8 9 9 9 9 9 9 5 4 2
CD19+ Number of Samples
All 22 21 23 23 23 23 21 20 15 13 9 4
Failed BTKi and Venetoclax 8 8 9 9 9 9 9 9 5 4 2